IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases

Bibliography

• VOLK H, ASADULLAH K, GALLAGHER G, SABAT R, GRUTZ G: IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol. (2001) 22(8):414-417.
   PubMedGoogle Scholar
• DONNELLY RP, SHEIKH F, KOTENKO SV, DICKENSHEETS H: The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol. (2004) 76(2):314-321.
   PubMedGoogle Scholar
• LANGER JA, CUTRONE EC, KOTENKO S: The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev. (2004) 15(1):33-48.
   PubMed Web of Science ®Google Scholar
• PESTKA S, KRAUSE CD, SARKAR D et al.: Interleukin-10 and related cytokines and receptors. Ann. Rev. Immunol. (2004) 22:929-979.
   PubMed Web of Science ®Google Scholar
• WOLK K, SABAT R: Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. (2006) 17(5):367-380.
   PubMed Web of Science ®Google Scholar
• WOLK K, KUNZ S, ASADULLAH K, SABAT R: Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol. (2002) 168(11):5397-5402.
   PubMed Web of Science ®Google Scholar
• KOTENKO SV, GALLAGHER G, BAURIN VV et al.: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. (2003) 4(1):69-77.
   PubMed Web of Science ®Google Scholar
• SHEPPARD P, KINDSVOGEL W, XU W et al.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. (2003) 4(1):63-68.
   PubMed Web of Science ®Google Scholar
• WALTER MR: Structural analysis of IL-10 and Type I interferon family members and their complexes with receptor. Adv. Protein Chem. (2004) 68:171-223.
   PubMedGoogle Scholar
• ZDANOV A: Structural features of the interleukin-10 family of cytokines. Curr. Pharm. Des. (2004) 10(31):3873-3884.
   PubMed Web of Science ®Google Scholar
• KOTENKO SV: The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. (2002) 13(3):223-240.
   PubMed Web of Science ®Google Scholar
• JOSEPHSON K, LOGSDON NJ, WALTER MR: Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity (2001) 15(1):35-46.
   PubMed Web of Science ®Google Scholar
• REINEKE U, SCHNEIDER-MERGENER J, GLASER RW et al.: Evidence for conformationally different states of interleukin-10: binding of a neutralizing antibody enhances accessibility of a hidden epitope. J. Mol. Recognit. (1999) 12(4):242-248.
   PubMedGoogle Scholar
• WOLK K, WITTE E, REINEKE U et al.: Is there an interaction between interleukin-10 and interleukin-22? Genes Immun. (2005) 6(1):8-18.
   PubMed Web of Science ®Google Scholar
• YOON SI, LOGSDON NJ, SHEIKH F, DONNELLY RP, WALTER MR: Conformational changes mediate interleukin-10 receptor 2(IL-10R2) binding to IL-10 and assembly of the signaling complex. J. Biol. Chem. (2006) 281(46):35088-35096.
   Google Scholar
• MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O’GARRA A: Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. (2001) 19:683-765.
   PubMed Web of Science ®Google Scholar
• WOLK K, KUNZ S, WITTE E et al.: IL-22 increases the innate immunity of tissues. Immunity (2004) 21(2):241-254.
   PubMed Web of Science ®Google Scholar
• BONIFACE K, BERNARD FX, GARCIA M et al.: IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. (2005) 174(6):3695-3702.
   PubMed Web of Science ®Google Scholar
• RADAEVA S, SUN R, PAN HN, HONG F, GAO B: Interleukin 22(IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology (2004) 39(5):1332-1342.
   PubMed Web of Science ®Google Scholar
• WOLK K, WITTE E, WALLACE E et al.: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. (2006) 36(5):1309-1323.
   PubMed Web of Science ®Google Scholar
• GALLAGHER G, DICKENSHEETS H, ESKDALE J et al.: Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun. (2000) 1(7):442-450.
   PubMed Web of Science ®Google Scholar
• BLUMBERG H, CONKLIN D, XU WF et al.: Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell (2001) 104(1):9-19.
   PubMed Web of Science ®Google Scholar
• LIAO YC, LIANG WG, CHEN FW et al.: IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α. J. Immunol. (2002) 169(8):4288-4297.
   PubMed Web of Science ®Google Scholar
• CHEN PJ, WEI CC, WANG C et al.: Promoter analysis of interleukin 19. Biochem. Biophys. Res. Commun. (2006) 344(3):713-720.
   PubMed Web of Science ®Google Scholar
• KINGO K, KOKS S, NIKOPENSIUS T, SILM H, VASAR E: Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. (2004) 5(2):117-121.
   PubMedGoogle Scholar
• KOKS S, KINGO K, RATSEP R et al.: Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun. (2004) 5(8):662-667.
   PubMed Web of Science ®Google Scholar
• KOKS S, KINGO K, VABR K et al.: Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun. (2005) 6(5):407-415.
   PubMed Web of Science ®Google Scholar
• CHANG C, MAGRACHEVA E, KOZLOV S et al.: Crystal structure of interleukin-19 defines a new subfamily of helical cytokines. J. Biol. Chem. (2003) 278(5):3308-3313.
   PubMedGoogle Scholar
• ZDANOV A: Structural studies of the interleukin-19 subfamily of cytokines. Vitam. Horm. (2006) 74:61-76.
   PubMedGoogle Scholar
• JORDAN WJ, ESKDALE J, BONIOTTO M et al.: Human IL-19 regulates immunity through auto-induction of IL-19 and production of IL-10. Eur. J. Immunol. (2005) 35(5):1576-1582.
   PubMed Web of Science ®Google Scholar
• KUNZ S, WOLK K, WITTE E et al.: Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp. Dermatol. (2006) 15(12):991-1004.
   PubMed Web of Science ®Google Scholar
• ZHONG H, WU Y, BELARDINELLI L, ZENG D: A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-α increase. Am. J. Respir. Cell Mol. Biol. (2006) 35(5):587-592.
   PubMed Web of Science ®Google Scholar
• HOSOI T, WADA S, SUZUKI S et al.: Bacterial endotoxin induces IL-20 expression in the glial cells. Brain Res. Mol. Brain Res. (2004) 130(1-2):23-29.
   PubMedGoogle Scholar
• CHEN WY, CHENG BC, JIANG MJ, HSIEH MY, CHANG MS: IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2006) 26(9):2090-2095.
   PubMedGoogle Scholar
• HSING CH, HO CL, CHANG LY et al.: Tissue microarray analysis of interleukin-20 expression. Cytokine (2006) 35(1-2):44-52.
   PubMedGoogle Scholar
• LIU L, DING C, ZENG W et al.: Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood (2003) 102(9):3206-3209.
   PubMed Web of Science ®Google Scholar
• LI HH, LIN YC, CHEN PJ et al.: Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br. J. Dermatol. (2005) 153(3):591-595.
   PubMed Web of Science ®Google Scholar
• OTKJAER K, KRAGBALLE K, FUNDING AT et al.: The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br. J. Dermatol. (2005) 153(5):911-918.
   PubMed Web of Science ®Google Scholar
• ROMER J, HASSELAGER E, NORBY PL et al.: Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J. Invest. Dermatol. (2003) 121(6):1306-1311.
   PubMed Web of Science ®Google Scholar
• WEI CC, CHEN WY, WANG YC et al.: Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. (2005) 117(1):65-72.
   PubMedGoogle Scholar
• OGILVIE AL, LUFTL M, ANTONI C et al.: Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-α. Int. J. Immunopathol. Pharmacol. (2006) 19(2):271-278.
   PubMed Web of Science ®Google Scholar
• HSU YH, LI HH, HSIEH MY et al.: Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. (2006) 54(9):2722-2733.
   PubMed Web of Science ®Google Scholar
• HSING CH, HSIEH MY, CHEN WY et al.: Induction of interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass. Ann. Thorac. Surg. (2006) 81(6):2196-2201.
   PubMedGoogle Scholar
• MENON R, ISMAIL L, ISMAIL D et al.: Human fetal membrane expression of IL-19 and IL-20 and its differential effect on inflammatory cytokine production. J. Matern. Fetal Neonatal Med. (2006) 19(4):209-214.
   PubMed Web of Science ®Google Scholar
• DUMOUTIER L, LEEMANS C, LEJEUNE D, KOTENKO SV, RENAULD JC: Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J. Immunol. (2001) 167(7):3545-3549.
   PubMed Web of Science ®Google Scholar
• PARRISH-NOVAK J, XU W, BRENDER T et al.: Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J. Biol. Chem. (2002) 277(49):47517-47523.
   PubMed Web of Science ®Google Scholar
• PLETNEV S, MAGRACHEVA E, KOZLOV S et al.: Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20. Biochemistry (2003) 42(43):12617-12624.
   PubMed Web of Science ®Google Scholar
• LIANG SC, TAN XY, LUXENBERG DP et al.: Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. (2006) 203(10):2271-2279.
   PubMed Web of Science ®Google Scholar
• LECART S, MOREL F, NORAZ N et al.: IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int. Immunol. (2002) 14(11):1351-1356.
   PubMed Web of Science ®Google Scholar
• GALLAGHER G, ESKDALE J, JORDAN W et al.: Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int. Immunopharmacol. (2004) 4(5):615-626.
   Google Scholar
• LIAO SC, CHENG YC, WANG YC et al.: IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J. Immunol. (2004) 173(11):6712-6718.
   PubMed Web of Science ®Google Scholar
• ORAL HB, KOTENKO SV, YILMAZ M et al.: Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur. J. Immunol. (2006) 36(2):380-388.
   PubMed Web of Science ®Google Scholar
• SANO S, CHAN KS, CARBAJAL S et al.: Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. (2005) 11(1):43-49.
   PubMed Web of Science ®Google Scholar
• CHAN JR, BLUMENSCHEIN W, MURPHY E et al.: IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. (2006) 203(12):2577-2587.
   PubMed Web of Science ®Google Scholar
• HSIEH MY, CHEN WY, JIANG MJ et al.: Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. (2006) 7(3):234-242.
   PubMed Web of Science ®Google Scholar
• HEUZE-VOURC’H N, LIU M, DALWADI H et al.: IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem. Biophys. Res. Commun. (2005) 333(2):470-475.
   PubMed Web of Science ®Google Scholar
• OLSEN NJ, STEIN CM: New drugs for rheumatoid arthritis. N. Engl. J. Med. (2004) 350(21):2167-2179.
   PubMed Web of Science ®Google Scholar
• PHILIPP S, WOLK K, KREUTZER S et al.: The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin. Ther. Targets (2006) 10(6):817-831.
   PubMed Web of Science ®Google Scholar
• STERRY W, STINGL G, LANGLEY RG et al.: Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial. J. Dtsch. Dermatol. Ges. (2006) 4(11):947-956.
   PubMedGoogle Scholar
• SURYAPRASAD AG, PRINDIVILLE T: The biology of TNF blockade. Autoimmun. Rev. (2003) 2(6):346-357.
   PubMed Web of Science ®Google Scholar